Merck (MRK.N), opens new tab is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker’s strategy to diversify beyond its blockbuster cancer treatment Keytruda.
The move adds to a growing list of high-profile transactions over the past decade by U.S. pharmaceutical companies to acquire promising therapies in fields ranging from oncology, neurology to rare diseases and obesity.
Globally, $105.3 billion worth of pharmaceuticals and biotech M&A deals have been inked so far in 2025, according to data compiled by LSEG, up 7% from year-ago levels and the highest year-to-date total since 2023.
Major deals involving U.S. drugmakers and biotechs over the past decade
Popular Categories
Previous article![]( "EU aims to stockpile critical medical supplies for future crises")
Next article![]( "Ambulatory Surgical Center Market Rising Amid Surge in Outpatient Procedures and Cost-Effective Care Delivery, 2025-2032")
